Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBOLD Prostate-304
jRCT2031260631Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Jan 2027
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of risvutatug rezetecan in prostate cancer (PCa) (2 arms), sponsored by GSK. Primary endpoints: Radiographic progression-free survival and Overall survival. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031260631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260631.